

Product datasheet for **TL302545V**

Twinkle (TWNK) Human shRNA Lentiviral Particle (Locus ID 56652)

Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	Twinkle (TWNK) Human shRNA Lentiviral Particle (Locus ID 56652)
Locus ID:	56652
Synonyms:	ATXN8; C10orf2; IOSCA; MTDPS7; PEO; PEO1; PEOA3; PRLTS5; SANDO; SCA8; TWINL
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	C10orf2 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 ⁷ TU/ml.
RefSeq:	NM_001163812 , NM_001163813 , NM_001163814 , NM_021830 , NM_021830.1 , NM_021830.2 , NM_021830.3 , NM_021830.4 , NM_001163814.1 , NM_001163812.1 , NM_001163813.1 , BC033762 , BC013349 , NR_160738 , NR_160740 , NR_160741 , NR_160742 , NM_001368275 , NR_160739 , NM_021830.5 , NM_001163812.2 , NM_001163814.2
UniProt ID:	Q96RR1
Summary:	This gene encodes a hexameric DNA helicase which unwinds short stretches of double-stranded DNA in the 5' to 3' direction and, along with mitochondrial single-stranded DNA binding protein and mtDNA polymerase gamma, is thought to play a key role in mtDNA replication. The protein localizes to the mitochondrial matrix and mitochondrial nucleoids. Mutations in this gene cause infantile onset spinocerebellar ataxia (IOSCA) and progressive external ophthalmoplegia (PEO) and are also associated with several mitochondrial depletion syndromes. Alternative splicing results in multiple transcript variants encoding distinct isoforms.[provided by RefSeq, Aug 2009]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service .



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).